Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Purpose Chemotherapy-induced nausea and vomiting (CINV) continues to be a common side effect of systemic anticancer therapy, decreasing quality of life and increasing resource utilization. The aim of this meta-analysis was to investigate the comparative efficacy and safety of palonosetron relative to other 5-HT3RAs.